



35Pharma Announces Oral Presentation at the 2024 American Thoracic Society International Conference

- Oral presentation will feature HS135, the Company's Phase 1 novel Activin and GDF inhibitor
- Selected to present during PAH focussed ATS Mini Symposium

Montreal, QC, Canada (Feb 1, 2024) – 35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today announced that it has been selected for an oral presentation at the 2024 American Thoracic Society (ATS) International Conference in San Diego, CA, USA (May 17 - 22, 2024).

The presentation will feature data on HS135, the Company's Phase 1 novel Activin and GDF inhibitor, in models of Pulmonary Hypertension and will form part of the thematic Mini Symposium: [Lessons learned from large scale clinical trials in PAH](#).

Details of the presentation are as follows:

Date: May 19th, 2024

Time of presentation: 9:39 AM - 9:51 AM

Location: San Diego Convention Center

Abstract: [6036 - HS135, A Novel Activin and GDF Trap, Is Highly Efficacious in Models of Group 1 and Group 2 Pulmonary Hypertension \(PH\)](#)

About 35Pharma

35Pharma is a clinical-stage biopharmaceutical company specializing in TGF-beta superfamily therapeutics for the treatment of Pulmonary Hypertension, Heart Failure and obesity. 35Pharma leverages its scientific leadership in TGF-beta biology combined with superior protein engineering to discover innovative compounds that selectively and potently neutralize validated pathological TGF-beta ligands while sparing beneficial homeostatic ligands.

Contact

Julia Schoelermann, VP Corporate Development, 35Pharma
info@35pharma.com

For more information, please visit www.35pharma.com